The present application demonstrates that HDAC inhibitors can be used in combination with IGF-1R inhibitors and mTOR inhibitors to treat prostate cancer. Combinations of the compounds, with or without HDAC inhibitors, and with or without androgen ablation therapy, can also be used, if indicated. The invention therefore provides methods of treatment and pharmaceutical compositions.
申请公布号
WO2009108857(A3)
申请公布日期
2010.01.14
申请号
WO2009US35464
申请日期
2009.02.27
申请人
COMBITHERA, INC.;KUSHNER, PETER;HARMON, CYRUS;HODGES-GALLAGHER, LESLIE;STAFFORD, WILLIAM
发明人
KUSHNER, PETER;HARMON, CYRUS;HODGES-GALLAGHER, LESLIE;STAFFORD, WILLIAM